

Chang Gong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103304/publications.pdf>

Version: 2024-02-01

47
papers

2,376
citations

361413

20
h-index

302126

39
g-index

47
all docs

47
docs citations

47
times ranked

4267
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-coding RNAs as new autophagy regulators in cancer progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166293.	3.8	6
2	circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. <i>Molecular Cancer</i> , 2022, 21, 8.	19.2	28
3	Pretreatment DCE-MRI-Based Deep Learning Outperforms Radiomics Analysis in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 846775.	2.8	12
4	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. <i>Science China Life Sciences</i> , 2022, 65, 2205-2217.	4.9	7
5	Predictive value of circulating tumor cells <i>FTH1</i> gene on the efficacy of neoadjuvant chemotherapy in non-metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12599-e12599.	1.6	0
6	Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low ⁺ expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS620-TPS620.	1.6	0
7	The ratio of PD1+CD8+T cells in stromal area of tumor tissue is associated with the effect of neoadjuvant chemotherapy in HER2 negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12626-e12626.	1.6	1
8	Differences in tumor microenvironment between HER2-positive and HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12562-e12562.	1.6	1
9	The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer. <i>Nature Cancer</i> , 2021, 2, 457-473.	13.2	31
10	Anti-PITPNM3 small molecular compounds reverse breast cancer metastasis by targeting PITPNM3.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15005-e15005.	1.6	1
11	BRMS1L inhibits bone metastasis of breast cancer cells through epigenetic silence of CXCR4.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13002-e13002.	1.6	0
12	Ultrasound-Guided Vacuum-assisted Biopsy Versus Surgical Resection in Patients With Breast Desmoid Tumor. <i>Journal of Surgical Research</i> , 2021, 261, 400-406.	1.6	0
13	Specimen number based diagnostic yields of suspicious axillary lymph nodes in core biopsy in breast cancer: clinical implications from a prospective exploratory study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2151-2161.	2.0	2
14	CTNND1 to mediate bone metastasis of triple-negative breast cancer via regulating CXCR4.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13045-e13045.	1.6	0
15	MiR-92b-3p Inhibits Proliferation of HER2-Positive Breast Cancer Cell by Targeting circCDYL. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 707049.	3.7	9
16	A new nomogram for predicting the malignant diagnosis of Breast Imaging Reporting and Data System (BI-RADS) ultrasonography category 4A lesions in women with dense breast tissue in the diagnostic setting. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3005-3017.	2.0	17
17	MiRNAs and Cancer: Key Link in Diagnosis and Therapy. <i>Genes</i> , 2021, 12, 1289.	2.4	44
18	Attenuation of PITPNM1 Signaling Cascade Can Inhibit Breast Cancer Progression. <i>Biomolecules</i> , 2021, 11, 1265.	4.0	1

#	ARTICLE	IF	CITATIONS
19	Silencing CTNND1 Mediates Triple-Negative Breast Cancer Bone Metastasis via Upregulating CXCR4/CXCL12 Axis and Neutrophils Infiltration in Bone. <i>Cancers</i> , 2021, 13, 5703.	3.7	13
20	Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2Âcm or smaller (T1N0) breast cancer. <i>Breast Cancer</i> , 2020, 27, 1147-1157.	2.9	6
21	<p>The Effect of Low and High Vacuum Drainage on the Postoperative Drainage of Breast Cancer: Insights from a Prospective, Non-Inferiority, Randomized Clinical Trial<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 12487-12496.	1.9	3
22	Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. <i>Molecular Cancer</i> , 2020, 19, 65.	19.2	143
23	Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e1044-e1054.	3.7	20
24	Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. <i>Cell Death and Disease</i> , 2019, 10, 55.	6.3	215
25	Effect of younger age on survival outcomes in T1N0M0 breast cancer: A propensity score matching analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 1039-1046.	1.7	22
26	A prognostic 10-miRNA risk score (10-miRNA RS) in predicting neoadjuvant chemotherapy sensitivity of luminal breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3139-3139.	1.6	0
27	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. <i>Nature Communications</i> , 2018, 9, 4274.	12.8	25
28	Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 775-786.	4.1	11
29	Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 748-759.	3.4	28
30	Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 197-216.	1.6	1
31	MicroRNAs and cancer: Key paradigms in molecular therapy (Review). <i>Oncology Letters</i> , 2017, 15, 2735-2742.	1.8	168
32	High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics. <i>Anticancer Research</i> , 2017, 37, 4329-4335.	1.1	11
33	HIF1Î±-associated circDENND4C Promotes Proliferation of Breast Cancer Cells in Hypoxic Environment. <i>Anticancer Research</i> , 2017, 37, 4337-4343.	1.1	77
34	Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis. <i>Oncotarget</i> , 2016, 7, 10373-10385.	1.8	37
35	Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 320.	2.6	115
36	Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 199-209.	6.1	43

#	ARTICLE	IF	CITATIONS
37	A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. <i>Oncotarget</i> , 2016, 7, 87312-87322.	1.8	12
38	Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 532-532.	1.6	0
39	NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. <i>Oncotarget</i> , 2015, 6, 32410-32425.	1.8	80
40	The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation. <i>Cell Reports</i> , 2015, 11, 111-124.	6.4	80
41	A Cytoplasmic NF- κ B Interacting Long Noncoding RNA Blocks κ B Phosphorylation and Suppresses Breast Cancer Metastasis. <i>Cancer Cell</i> , 2015, 27, 370-381.	16.8	794
42	E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. <i>Oncotarget</i> , 2015, 6, 31944-31957.	1.8	62
43	Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stem-like Cell Traits in Breast Cancer. <i>Cancer Research</i> , 2014, 74, 3603-3616.	0.9	68
44	BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. <i>Nature Communications</i> , 2014, 5, 5406.	12.8	84
45	Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer. <i>Journal of Surgical Research</i> , 2014, 189, 48-56.	1.6	13
46	Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer. <i>PLoS ONE</i> , 2010, 5, e15630.	2.5	60
47	A Double-blind Randomized Controlled Trial of Toremifen Therapy for Mastalgia. <i>Archives of Surgery</i> , 2006, 141, 43.	2.2	25